In the company’s news Friday,
Anesiva, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) to expand the indication for Zingo(TM) to treat adults’ pain associated with blood draws. Previously, Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system was only approved to treat the pain caused by peripheral IV insertions and blood draws in children aging 3-18 years.
As announced in November of last year, Anesiva ceased Zingo commercial activities to focus efforts on the development of Adlea(TM). This non-opioid, long-acting analgesic drug candidate was designed to manage the acute pain that follows orthopedic surgeries. Anesiva has intentions to license Zingo as well as the underlying drug delivery technology and intellectual property.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
